AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to AstraZeneca's (AZN) cancer drugs, Enhertu and Lynparza, for treating certain patients with breast cancer.

AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer

Check Point Software Technologies

T-Mobile US

Through June 24th, all but 16 of the popular benchmark's names were in the red for 2022. At the other end of the spectrum is an unlikely collection of stocks that have boldly bucked the market trend.

These 3 Nasdaq-100 Leaders Have More Upside

AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.

AstraZeneca Enhertu breast cancer drug is recommended for EU approval

Daiichi Sankyo Co Ltd

TOKYO & MUNICH--(BUSINESS WIRE)--Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2+ mBC Treated with a Prior Anti-HER2-Based Regimen

Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Apple

They both pay dividends and have some great growth potential.

2 Safe Stocks to Buy in This Bear Market

Costco

Chevron

JPMorgan Chase & Co

Lockheed Martin

Pfizer

Blue-chip stocks that are worth accumulating in the market correction. Undervalued blue-chip stocks with robust cash flows.

7 Blue-Chip Stocks to Buy and Hold for the Long-Haul

TOKYO & MUNICH--(BUSINESS WIRE)--Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR+ and HR- Disease

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®

Ionis Pharma

U.S.-listed shares of AstraZeneca AZN, +2.98% were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its primary endpoints in a Phase 3 clinical trial. AstraZeneca is developing eplontersen with Ionis Pharmaceuticals Inc. IONS, +5.54% ; shares in Ionis were up 5.1% on Tuesday.

AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this year

AutoZone

Enterprise Products Partners

AT&T

These rock-solid companies can help investors navigate a market rife with recession risk.

4 of the Safest Stocks to Buy If the U.S. Dips Into a Recession

AstraZeneca PLC (LSE:AZN) will file a new drug application later this year after a successful phase III clinical trial of a treatment for a rare hereditary disease. Eplontersen hit all its goals when researchers used it on people with transthyretin-mediated amyloid polyneuropathy.

AstraZeneca hails phase III success of drug for rare disease amyloid polyneuropathy

Mereo Biopharma Group Plc - ADR

AstraZeneca AZN, +0.48% AZN, +0.42% is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma MREO, +16.03% , The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialist's partners, which include Novartis NVS, +0.60% , OncXerna and Ultragenyx RARE, -1.36%.

AstraZeneca weighing bid for Mereo BioPharma: report

AstraZeneca's already diverse business just got another boost.

This Cancer Drug's News Could Mean Another Blockbuster for AstraZeneca

AstraZeneca PLC (LSE:AZN) shares have been downgraded by UBS on the basis that there are “no major catalysts” in its drug pipeline for the rest of the year. The shares are currently trading on a small discount to the wider pharma sector on full year forecast earnings, and a 10% discount on 2025 earnings, the Swiss bank noted.

AstraZeneca downgraded by UBS on lack of catalysts until 2023

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer

TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer

GlaxoSmithKline

Novartis

Sanofi

Vaxart

It depends on which subsector you're talking about.

What Could a Recession Mean for Healthcare Stocks?

SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--EpimAb Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer

EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer

An up to 31% plunge in the Nasdaq is the perfect excuse to put your money to work in these three steady businesses.

Nasdaq Bear Market: 3 of the Safest Stocks on the Planet to Buy Right Now

Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.

AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half

AstraZeneca PLC (LSE:AZN) was among the few failing to benefit from the post-Jubilee bounce that sent stocks higher despite unveiling promising results at the weekend for its Enhertu breast cancer treatment.   The pharma giant reportedly received a standing ovation when it announced the results of its DESTINY-Breast04 clinical trials on metastatic breast cancer treatment at the seminal ASCO cancer conference on Sunday, but even so its shares were down 3.58% at 10,068p per share.

AstraZeneca wows peers but misses out on post-Jubilee bounce

The American Society of Clinical Oncology met for its annual conference in Chicago over the weekend.

AstraZeneca's Breast Cancer Drug Beats Expectations, and Other ASCO Highlights

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer

ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

Innate Pharma SA

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces IPH5201 Phase 2 study in lung cancer

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Illumina

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL announced a broad strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic assays.

GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage Cancer

Gilead Sciences

Roche Holding AG

Investors will want to keep an eye on developments at this week's meeting of the American Society of Clinical Oncology in Chicago, where four members of big pharma will share study results of their most promising cancer drugs. The news has the potential to move the shares of the presenters-- Daiichi Sankyo Co. Ltd.

ASCO Presentations Could Move Shares of Daiichi, AstraZeneca, Gilead and Roche

News for AstraZeneca Stock (AZN)